
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2647372/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum. JAMA Neurology, 2022, 79, 228.	4.5	97
2	Six generations of <i>CHMP2B</i> â€mediated Frontotemporal Dementia: Clinical features, predictive testing, progression, and survival. Acta Neurologica Scandinavica, 2022, 145, 529-540.	1.0	4
3	Replication study of plasma proteins relating to Alzheimer's pathology. Alzheimer's and Dementia, 2021, 17, 1452-1464.	0.4	13
4	Middle-Aged Man Concerned about His Family History. , 2021, , 54-58.		0
5	Cortical Frontoparietal Network Dysfunction in -Frontotemporal Dementia. Frontiers in Aging Neuroscience, 2021, 13, 714220.	1.7	0
6	Dickkopf-1 Overexpression in vitro Nominates Candidate Blood Biomarkers Relating to Alzheimer's Disease Pathology. Journal of Alzheimer's Disease, 2020, 77, 1353-1368.	1.2	7
7	Validation of Plasma Proteomic Biomarkers Relating to Brain Amyloid Burden in the EMIF-Alzheimer's Disease Multimodal Biomarker Discovery Cohort. Journal of Alzheimer's Disease, 2020, 74, 213-225.	1.2	13
8	Discovery and validation of plasma proteomic biomarkers relating to brain amyloid burden by SOMAscan assay. Alzheimer's and Dementia, 2019, 15, 1478-1488.	0.4	46
9	Primary fatty amides in plasma associated with brain amyloid burden, hippocampal volume, and memory in the European Medical Information Framework for Alzheimer's Disease biomarker discovery cohort. Alzheimer's and Dementia, 2019, 15, 817-827.	0.4	62
10	Cerebrospinal fluid biomarkers of neurodegeneration, synaptic integrity, and astroglial activation across the clinical Alzheimer's disease spectrum. Alzheimer's and Dementia, 2019, 15, 644-654.	0.4	90
11	A metaboliteâ€based machine learning approach to diagnose Alzheimerâ€type dementia in blood: Results from the European Medical Information Framework for Alzheimer disease biomarker discovery cohort. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2019, 5, 933-938.	1.8	70
12	Potential genetic modifiers of disease risk and age at onset in patients with frontotemporal lobar degeneration and GRN mutations: a genome-wide association study. Lancet Neurology, The, 2018, 17, 548-558.	4.9	97
13	Prevalence of the apolipoprotein E ε4 allele in amyloid β positive subjects across the spectrum of Alzheimer's disease. Alzheimer's and Dementia, 2018, 14, 913-924.	0.4	58
14	Association of Cerebral Amyloid-β Aggregation With Cognitive Functioning in Persons Without Dementia. JAMA Psychiatry, 2018, 75, 84.	6.0	133
15	Amyloid-β, Tau, and Cognition in Cognitively Normal Older Individuals: Examining the Necessity to Adjust for Biomarker Status in Normative Data. Frontiers in Aging Neuroscience, 2018, 10, 193.	1.7	16
16	Inflammatory markers of CHMP2B-mediated frontotemporal dementia. Journal of Neuroimmunology, 2018, 324, 136-142.	1.1	10
17	Early-Onset Dementia. Alzheimer Disease and Associated Disorders, 2017, 31, 146-151.	0.6	12
18	The frequency and influence of dementia risk factors in prodromal Alzheimer's disease. Neurobiology of Aging, 2017, 56, 33-40.	1.5	27

2

#	Article	IF	CITATIONS
19	Relation of Odor Identification with Alzheimer's Disease Markers in Cerebrospinal Fluid and Cognition. Journal of Alzheimer's Disease, 2017, 60, 1025-1034.	1.2	33
20	Memory Correlates of Alzheimer's Disease Cerebrospinal Fluid Markers: A Longitudinal Cohort Study. Journal of Alzheimer's Disease, 2017, 60, 1119-1128.	1.2	27
21	A Danish adaptation of the Boston Naming Test: preliminary norms for older adults and validity in mild Alzheimer's disease. Clinical Neuropsychologist, 2017, 31, 72-87.	1.5	14
22	TMEM106B and ApoE polymorphisms in CHMP2B-mediated frontotemporal dementia (FTD-3). Neurobiology of Aging, 2017, 59, 221.e1-221.e7.	1.5	4
23	[P2–534]: FIRST YEAR DATA FROM THE DANISH NATIONAL DEMENTIA CLINICAL QUALITY DATABASE. Alzheimer's and Dementia, 2017, 13, P846.	0.4	Ο
24	Early microgliosis precedes neuronal loss and behavioural impairment in mice with a frontotemporal dementia-causing CHMP2B mutation. Human Molecular Genetics, 2017, 26, ddx003.	1.4	22
25	Moderate-to-High Intensity Physical Exercise in Patients with Alzheimer's Disease: A Randomized Controlled Trial. Journal of Alzheimer's Disease, 2016, 50, 443-453.	1.2	210
26	P4â€122: Prevalence of Vascular Risk Factors in Different Stages of Prodromal Alzheimer's Disease and Its Influence on Cognitive Decline. Alzheimer's and Dementia, 2016, 12, P1059.	0.4	0
27	P4â€184: Shift in Cerebral PET Glucose Metabolism in Frontotemporal Dementia Linked to Chromosome 3 (FTDâ€3) from the Presymptomatic to Symtomatic Stage. Alzheimer's and Dementia, 2016, 12, P1090.	0.4	1
28	Effect of aerobic exercise on physical performance in patients with Alzheimer's disease. Alzheimer's and Dementia, 2016, 12, 1207-1215.	0.4	76
29	O1-03-03: Olfactory dysfunction may predict Alzheimer's disease related tau pathology in cerebrospinal fluid (CSF). , 2015, 11, P130-P130.		0
30	O4-03-01: Early detection of Alzheimer's disease (AD)-related amyloid and tau pathology: A computerized versus a paper-and-pencil memory test. , 2015, 11, P272-P272.		0
31	Frontotemporal dementia caused by CHMP2B mutation is characterised by neuronal lysosomal storage pathology. Acta Neuropathologica, 2015, 130, 511-523.	3.9	79
32	Dementia Diagnosis, Treatment, and Care in Specialist Clinics in Two Scandinavian Countries: A Data Comparison between the Swedish Dementia Registry (SveDem) and the Danish Dementia Registry. Journal of Alzheimer's Disease, 2015, 48, 229-239.	1.2	22
33	O3-11-02: Prevalence and diagnostic procedures in early-onset dementia in tertiary referral center patients in denmark, sweden, and the netherlands. , 2015, 11, P244-P245.		0
34	O5-04-06: Moderate to high-intensity physical exercise in patients with Alzheimer's disease. , 2015, 11, P324-P325.		2
35	Prevalence of Cerebral Amyloid Pathology in Persons Without Dementia. JAMA - Journal of the American Medical Association, 2015, 313, 1924.	3.8	1,166
36	Frequency and Severity of Semantic Deficits in a Consecutive Memory Clinic Cohort. Dementia and Geriatric Cognitive Disorders, 2014, 38, 214-223.	0.7	11

#	Article	IF	CITATIONS
37	Cognitive impairment in the preclinical stage of dementia in FTD-3 <i>CHMP2B</i> mutation carriers: a longitudinal prospective study. Journal of Neurology, Neurosurgery and Psychiatry, 2013, 84, 170-176.	0.9	19
38	Corticobasal and ataxia syndromes widen the spectrum of <i>C9ORF72</i> hexanucleotide expansion disease. Clinical Genetics, 2013, 83, 279-283.	1.0	128
39	Preserving Cognition, Quality of Life, Physical Health and Functional Ability in Alzheimer's Disease: The Effect of Physical Exercise (ADEX Trial): Rationale and Design. Neuroepidemiology, 2013, 41, 198-207.	1.1	44
40	Brain Energy Metabolism and Blood Flow Differences in Healthy Aging. Journal of Cerebral Blood Flow and Metabolism, 2012, 32, 1177-1187.	2.4	145
41	Presymptomatic cerebral blood flow changes in <i>CHMP2B</i> mutation carriers of familial frontotemporal dementia (FTD-3), measured with MRI. BMJ Open, 2012, 2, e000368.	0.8	13
42	<scp>EFNS</scp> task force: the use of neuroimaging in the diagnosis of dementia. European Journal of Neurology, 2012, 19, 1487-1501.	1.7	112
43	Reversal of pathology in CHMP2Bâ€mediated frontotemporal dementia patient cells using RNA interference. Journal of Gene Medicine, 2012, 14, 521-529.	1.4	14
44	Development of a dementia assessment quality database. Aging and Mental Health, 2011, 15, 40-46.	1.5	14
45	Frontotemporal Dementia Caused by CHMP2B Mutations. Current Alzheimer Research, 2011, 8, 246-251.	0.7	85
46	FUS pathology defines the majority of tau- and TDP-43-negative frontotemporal lobar degeneration. Acta Neuropathologica, 2010, 120, 33-41.	3.9	222
47	Disruption of endocytic trafficking in frontotemporal dementia with CHMP2B mutations. Human Molecular Genetics, 2010, 19, 2228-2238.	1.4	163
48	Presymptomatic Generalized Brain Atrophy in Frontotemporal Dementia Caused by <i>CHMP2B</i> Mutation. Dementia and Geriatric Cognitive Disorders, 2009, 27, 182-186.	0.7	17
49	Validation of Alzheimer's disease CSF and plasma biological markers: The multicentre reliability study of the pilot European Alzheimer's Disease Neuroimaging Initiative (E-ADNI). Experimental Gerontology, 2009, 44, 579-585.	1.2	60
50	The diagnostic efficiency of biomarkers in sporadic Creutzfeldt-Jakob disease compared to Alzheimer's disease. Neurobiology of Aging, 2009, 30, 1834-1841.	1.5	46
51	Cortical volumes and atrophy rates in FTD-3 CHMP2B mutation carriers and related non-carriers. NeuroImage, 2009, 45, 713-721.	2.1	28
52	Validation of the Danish Addenbrooke's Cognitive Examination as a Screening Test in a Memory Clinic. Dementia and Geriatric Cognitive Disorders, 2009, 27, 361-365.	0.7	42
53	The pilot European Alzheimer's Disease Neuroimaging Initiative of the European Alzheimer's Disease Consortium. , 2008, 4, 255-264.		39
54	Usability of Cerebrospinal Fluid Biomarkers in a Tertiary Memory Clinic. Dementia and Geriatric Cognitive Disorders, 2008, 25, 553-558.	0.7	11

#	Article	IF	CITATIONS
55	A Reassessment of the Neuropathology of Frontotemporal Dementia Linked to Chromosome 3. Journal of Neuropathology and Experimental Neurology, 2007, 66, 884-891.	0.9	118
56	Assessing Therapeutic Efficacy in a Progressive Disease. CNS Drugs, 2006, 20, 311-325.	2.7	57
57	Mutations in the endosomal ESCRTIII-complex subunit CHMP2B in frontotemporal dementia. Nature Genetics, 2005, 37, 806-808.	9.4	752
58	Cerebral Metabolic Response to Low Blood Flow: Possible Role of Cytochrome Oxidase Inhibition. Journal of Cerebral Blood Flow and Metabolism, 2005, 25, 1183-1196.	2.4	90
59	Frontotemporal Dementia Linked to Chromosome 3. Dementia and Geriatric Cognitive Disorders, 2004, 17, 274-276.	0.7	8
60	Long-Term Cholinesterase Inhibitor Treatment of Alzheimer???s Disease. CNS Drugs, 2004, 18, 757-768.	2.7	53
61	Cerebral functional anatomy of voluntary contractions of ankle muscles in man. Journal of Physiology, 2001, 535, 397-406.	1.3	35
62	Dementia with Impaired Temporal Glucose Metabolism in Late-Onset Metachromatic Leukodystrophy. Dementia and Geriatric Cognitive Disorders, 2001, 12, 85-88.	0.7	18
63	Cerebral activation during bicycle movements in man. Experimental Brain Research, 2000, 135, 66-72.	0.7	177
64	Cortical Centres Underlying Auditory Temporal Processing in Humans: A PET Study. International Journal of Audiology, 2000, 39, 30-37.	0.9	21
65	Stimulus-dependent central processing of auditory stimuli: A PET study. Scandinavian Audiology, 1999, 28, 161-169.	0.5	57
66	Ageing and dementia.: Edited by K. Jellinger, F. Fazekas and M. Windisch. Published by Springer-Verlag, Vienna, 1998. 406 pp. Price US\$ 159; DM. Acta Psychiatrica Scandinavica, 1999, 99, 82-82.	2.2	0
67	Positron emission tomography of cortical centers of tinnitus. Hearing Research, 1999, 134, 133-144.	0.9	211
68	Cortical Responses to Sustained and Divided Attention in Alzheimer's Disease. NeuroImage, 1999, 10, 269-281.	2.1	71
69	Activation of Human Extrageniculostriate Pathways after Damage to Area V1. NeuroImage, 1999, 9, 97-107.	2.1	44
70	Cerebral Blood Flow Measurements by Magnetic Resonance Imaging Bolus Tracking: Comparison with [150]H2O Positron Emission Tomography in Humans. Journal of Cerebral Blood Flow and Metabolism, 1998, 18, 935-940.	2.4	212
71	Cerebral blood-flow changes evoked by two levels of painful heat stimulation: A positron emission tomography study in humans. European Journal of Pain, 1998, 2, 95-106.	1.4	29
72	Origin of Human Motor Readiness Field Linked to Left Middle Frontal Gyrus by MEG and PET. Neurolmage, 1998, 8, 214-220.	2.1	75

#	Article	IF	CITATIONS
73	Cortical Sites of Sustained and Divided Attention in Normal Elderly Humans. NeuroImage, 1997, 6, 145-155.	2.1	74
74	Epilepsy in Down syndrome—prevalence in three age groups. Seizure: the Journal of the British Epilepsy Association, 1996, 5, 121-125.	0.9	30
75	The Prevalence of Dementia in Down Syndrome. Dementia and Geriatric Cognitive Disorders, 1996, 7, 221-225.	0.7	12